Zobrazeno 1 - 10
of 269
pro vyhledávání: '"BOLOGNESI ML"'
Autor:
Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML
Publikováno v:
Journal of medicinal chemistry 61 (2018): 7640–7656. doi:10.1021/acs.jmedchem.8b0061010.1021/acs.jmedchem.8b00610
info:cnr-pdr/source/autori:Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML/titolo:Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 beta and Tau-Aggregation Inhibitors/doi:10.1021%2Facs.jmedchem.8b0061010.1021%2Facs.jmedchem.8b00610/rivista:Journal of medicinal chemistry/anno:2018/pagina_da:7640/pagina_a:7656/intervallo_pagine:7640–7656/volume:61
info:cnr-pdr/source/autori:Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML/titolo:Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 beta and Tau-Aggregation Inhibitors/doi:10.1021%2Facs.jmedchem.8b0061010.1021%2Facs.jmedchem.8b00610/rivista:Journal of medicinal chemistry/anno:2018/pagina_da:7640/pagina_a:7656/intervallo_pagine:7640–7656/volume:61
Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3? and tau aggregati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=cnr_________::9cce7dd9e5c7b60c33c184ab24673788
The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule and biological drug candidates. One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d4949ecce1093ce8efab32e5ef18ab21
http://hdl.handle.net/11585/623060
http://hdl.handle.net/11585/623060
Autor:
Bolognesi, Ml, Staderini, M., Tran, H. N. A., Monaco, A., López Cobeñas, A., Bongarzone, S., Biarnés, X., López Alvarado, P., Cabezas, N., Carloni, P., Menéndez, J. C., Legname, Giuseppe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______288::25bfb5ab62d351e135d79d13bb4546e2
http://hdl.handle.net/20.500.11767/15573
http://hdl.handle.net/20.500.11767/15573